Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of Olmesartan Medoxomil (CAS: 144689-63-4) with high quality, commercial production. We can provide Certificate of Analysis (COA), Safety Data Sheet (SDS), worldwide delivery, small and bulk quantities available, strong after-sale service. Welcome to order. Please contact: alvin@ruifuchem.com
| Chemical Name |
Olmesartan Medoxomil |
| Synonyms |
4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2H-tetazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic Acid (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl Ester; CS-866 |
| CAS Number |
144689-63-4 |
| CAT Number |
RF-PI1730 |
| Stock Status |
In Stock, Production Scale Up to Tons |
| Molecular Formula |
C29H30N6O6 |
| Molecular Weight |
558.60 |
| Melting Point |
180℃ (dec.) |
| Water Solubility |
Insoluble in Water; Slightly Soluble in DMSO |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
White to Almost White Cyrstalline Powder |
| Identification |
IR, HPLC, UV: Must Conform to Reference Standard |
| Purity / Analysis Method |
>99.5% (HPLC on the Anhydrous and Solvent-Free Basis) |
| Loss on Drying |
<0.50% |
| Residue on Ignition |
<0.10% |
| Related Substances |
|
| Olmesartan RRT 0.2 |
<0.50% |
| Olmesartan Medoxoil Related Compound A. RRT 0.7 |
<0.20% |
| Olefinic Impurity RRT 1.6 |
<0.50% |
| N-Alkyl Impurity RRT 3.4 |
<0.10% |
| Any Other Impurity |
<0.10% |
| Total Impurities |
<0.50% |
| Heavy Metals (as Pb) |
<10ppm |
| pH of Solution (2%, W/V) |
4.5 to 6.5 |
| Test Standard |
Enterprise Standard; USP Standard |
| Usage |
API |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture
Olmesartan Medoxomil (CS-866) (CAS: 144689-63-4) is a potent and selective angiotensin II type 1 (AT(1)) receptor antagonist with IC50 of 66.2 μM., used in the treatment of high blood pressure. Used as an anti-hypertensive. Olmesartan works by blocking the binding of angiotensin II to the AT1 receptors in vascular muscle. By blocking the binding rather than the synthesis of angiotensin II, Olmesartan inhibits the negative regulatory feedback on renin secretion. Olmesartan Medoxomil is a pro-drug that is de-esterified to the active metabolite, olmesartan. Olmesartan Medoxomil was launched in the US as Benicar, an orally administered treatment for hypertension.